Evidence map›Paper›PMID 31023281›Full record

Trial reportBMC public health2019

Intimate partner violence, depression, and sexual behaviour among gay, bisexual and other men who have sex with men in the PROUD trial.

Ada R Miltz, Fiona C Lampe, Loraine J Bacchus, Sheena McCormack, David Dunn, Ellen White, Alison Rodger, Andrew N Phillips, Lorraine Sherr, Amanda Clarke and 3 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02065986 (Pre-exposure Option for Reducing HIV in the UK), which is not on this map. Cited by 42 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 5 pooled it
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02065986 phase4completednot on this map

Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD)

TypeinterventionalSponsorMRC [ycm]Ran2012 to 2016Enrolled544ConditionsHIVArmsTruvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 5 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Ada R MiltzCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK. Ada.Miltz.11@ucl.ac.uk.
Fiona C LampeCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
Loraine J BacchusDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Sheena McCormackMRC Clinical Trials Unit, University College London, London, UK.
David DunnMRC Clinical Trials Unit, University College London, London, UK.
Ellen WhiteMRC Clinical Trials Unit, University College London, London, UK.
Alison RodgerCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
Andrew N PhillipsCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
Lorraine SherrCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, UK.
Amanda ClarkeElton John Centre, Sussex House, Brighton, UK.
Alan McOwan56 Dean Street, London, UK.
Ann SullivanChelsea & Westminster NHS Foundation Trust, London, UK.
Mitzy GafosDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
University College London · GBLondon School of Hygiene & Tropical Medicine · GBChelsea and Westminster Hospital NHS Foundation Trust · GBKennedy Martin Health Outcomes (United Kingdom) · GB

Funding

Medical Research Council MC_UU_12023/23Medical Research Council MRC_UU_12023/23
6 · The paper itself

Abstract

backgroundLittle is known about the prevalence and correlates of intimate partner violence (IPV) among gay, bisexual and other men who have sex with men (GBMSM) in the UK. The aim of this study was to investigate the prevalence of IPV, associations of socio-economic and psychosocial factors with IPV, and the association of IPV with depression and sexual behaviour, among GBMSM in the PROUD trial of pre-exposure prophylaxis (PrEP).

methodsPROUD enrolled 544 HIV-negative participants in England from 2012 to 2014; participants were randomised to immediate or deferred PrEP. This analysis included 436 GBMSM who had IPV data at month-12 and/or 24. Prevalence of IPV victimization and perpetration (lifetime, and in the past year) was assessed at these time-points. Generalized estimating equations were used to investigate associations with IPV, using pooled data from both time-points.

resultsAt month-12 (N = 410), 44.9% of men reported ever being a victim of IPV, 15.6% in the last year, and 19.5% reported ever perpetrating IPV, 7.8% in the last year. At month-24 (N = 333), the corresponding prevalence was 40.2 and 14.7% for lifetime and past year IPV victimization and 18.0 and 6.9% for lifetime and past year IPV perpetration. IPV prevalence did not differ by randomised arm. Men reporting internalized homophobia and sexualized drug use were more likely to report IPV. Lifetime and last year experience of IPV victimization and perpetration were strongly associated with depressive symptoms (PHQ-9 ≥ 10) (adjusted for socio-demographics: lifetime IPV victimization PR 2.57 [95% CI: 1.71, 3.86]; past year IPV victimization PR 2.93 [95% CI: 1.96, 4.40]; lifetime IPV perpetration PR 2.87 [95% CI: 1.91, 4.32]; past year IPV perpetration PR 3.47 [95% CI: 2.13, 5.64], p < 0.001 for all); IPV was not consistently associated with measures of condomless anal sex or high partner numbers.

conclusionsGBMSM at high-risk of HIV who are seeking/taking PrEP may experience a high burden of IPV, which may be linked to depression. Training on awareness of and enquiry for IPV among GBMSM in sexual health clinics is recommended.

trial registrationClinicalTrials.gov identifier: NCT02065986 . Registered 19 February 2014 (retrospectively registered).

Indexed as

AdolescentAdultCrime VictimsDepressionEnglandHIV InfectionsHumansIntimate Partner ViolenceMaleMiddle AgedPre-Exposure ProphylaxisPrevalenceSexual and Gender MinoritiesSexual BehaviorSexual PartnersSubstance-Related DisordersDepressionHIVIntimate partner violence (IPV)Men who have sex with men (MSM)Pre-exposure prophylaxis (PrEP)Sexual risk behaviourSTI

Identifiers

PMID31023281
PMCPMC6482482
OpenAlexW2946741196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.